5'-BzH-2'-OMe-Ur-3'-Methoxyphosphoramidite
5'-BzH-2'-OMe-Ur-3'-Methoxyphosphoramidite - N (Normal) is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Specifications
Specifications
-
Catalog No.PR5-015
-
SMILESO=C1C=CN([C@H]2[C@H](OC)[C@H](OP(OC)N(C(C)C)C(C)C)[C@@H](CO[Si](OC(C3=CC=CC=C3)C4=CC=CC=C4)(O[Si](C)(C)C)O[Si](C)(C)C)O2)C(N1)=O
-
Molecular FormulaC36H58N3O10PSi3
-
Molecular Weight808.09
-
AppearanceColorless or faint yellow oil
-
PurityHPLC≥97.0%
-
Storage Condition-20℃
Documentation
Documentation
-
Catalog No.PR5-015
-
SMILESO=C1C=CN([C@H]2[C@H](OC)[C@H](OP(OC)N(C(C)C)C(C)C)[C@@H](CO[Si](OC(C3=CC=CC=C3)C4=CC=CC=C4)(O[Si](C)(C)C)O[Si](C)(C)C)O2)C(N1)=O
-
Molecular FormulaC36H58N3O10PSi3
-
Molecular Weight808.09
-
AppearanceColorless or faint yellow oil
-
PurityHPLC≥97.0%
-
Storage Condition-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Integrated Supply & Commercial Scale
With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

